Literature DB >> 26795677

HIV testing patterns for United States Air Force personnel, 2008-2012.

R K Kugblenu1, P S Paulin2, K J Tastad2, J F Okulicz3.   

Abstract

OBJECTIVE: This study evaluated 3rd generation human immunodeficiency virus (HIV) test patterns and HIV infection rates in the United States Air Force (USAF). STUDY
DESIGN: Retrospective database study.
METHODS: HIV enzyme-linked immunoassay (ELISA) and Western blot tests were analysed for all USAF personnel from 2008 to 2012. For new HIV cases, unadjusted and adjusted annual rates were calculated per 100,000 persons.
RESULTS: In total, 1,608,665 tests were performed in 626,298 individuals, with a reactive ELISA observed in 809 (0.001%) persons. Western blot (n = 1949) results included 378 (19.4%) positive, 1283 (65.8%) negative, and 288 (15.0%) indeterminate (WBi). Unadjusted annual HIV rates were between 16.7 and 20.6 per 100,000 persons during the study period. The overall age-adjusted rate was 14.8 cases per 100,000 persons tested. Blacks/African Americans had the highest risk of HIV (risk ratio 7.9 [95% confidence interval 5.78, 9.95] compared to Whites).
CONCLUSIONS: WBi results, which can cause delays in determining HIV status, were relatively common with the 3rd generation assay. However, this will be mitigated by a planned transition to a 4th generation assay. Although the overall rate of HIV in the USAF is lower than US civilian adults, HIV prevention efforts targeting young Blacks/African Americans may help to reduce HIV incidence in the USAF. Published by Elsevier Ltd.

Entities:  

Keywords:  ELISA; HIV incidence; HIV infection; Indeterminate western blot

Mesh:

Year:  2016        PMID: 26795677     DOI: 10.1016/j.puhe.2015.11.019

Source DB:  PubMed          Journal:  Public Health        ISSN: 0033-3506            Impact factor:   2.427


  1 in total

1.  Physical fitness characteristics of active duty US Air Force members with HIV infection.

Authors:  Asha De; Xiaohe Xu; James White; Thankam S Sunil; Jason F Okulicz
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.